US · TMDX · MEDICAL - DEVICES
TransMedics Group, Inc. (TMDX) intrinsic value and stock valuation
$85.25as of 2026-11-21 · Mkt cap 2.9B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
TransMedics Group, Inc. DCF and intrinsic value
InvestorsCraft values TMDX with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from TMDX’s statements →
TransMedics Group, Inc. Graham Number
Graham Number: $41.87d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Glaukos Corporation (GKOS) $237.31
- Kymera Therapeutics, Inc. (KYMR) $115.31
- Immunovant, Inc. (IMVT) $31.77
- Bruker Corporation (BRKR) $56.46
- Oscar Health, Inc. (OSCR) $24.73
- Hinge Health, Inc. (HNGE) $105.78
- Indivior Pharmaceuticals Inc (INDV) $36.28
- Option Care Health, Inc. (OPCH) $31.59
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $605.5M | $441.5M | $241.6M | $93.5M | $30.3M |
| Operating income | $108.6M | $37.5M | -$-28.73M | -$-31.44M | -$-39.43M |
| Net income | $190.3M | $35.5M | -$-25.03M | -$-36.23M | -$-44.22M |
| EPSd | $4.69M | $1.01M | -$-769.68K | -$-1.23M | -$-1.6M |
| Operating cash flow | $192.8M | $48.8M | -$-13.03M | -$-45.82M | -$-28.86M |
| Capital expenditure | -$-59.25M | -$-129.74M | -$-179.06M | -$-11.91M | -$-3.52M |
| Free cash flow | $133.6M | -$-80.94M | -$-192.09M | -$-57.72M | -$-32.38M |
| Total assets | $1.07B | $804.1M | $706.1M | $277.2M | $134.9M |
| Total debt | $469.7M | $518.3M | $516M | $67.6M | $43.8M |
| Net debt | -$-18.68M | $181.6M | $121.1M | -$-133.63M | $18.2M |
| Total equity | $473.1M | $228.6M | $137.2M | $187.4M | $67.9M |
| Cash and short-term investments | $488.4M | $336.7M | $394.8M | $201.2M | $92.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $605.5M | $441.5M | $241.6M | $93.5M | $30.3M |
| Cost of revenue | $242.7M | $179.5M | $87.5M | $28.2M | $9.1M |
| Gross profit | $362.8M | $262.1M | $154.1M | $65.3M | $21.2M |
| Research and development expenses | $69.1M | $56M | $63.3M | $26.8M | $22.3M |
| Selling, general and administrative expenses | $185.2M | $168.6M | $119.6M | $69.9M | $38.3M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $254.2M | $224.6M | $182.8M | $96.7M | $60.6M |
| Cost and expenses | $496.9M | $404M | $270.4M | $124.9M | $69.7M |
| Interest income | $0.00 | $0.00 | $12.5M | $900K | $0.00 |
| Interest expense | $13.8M | $14.4M | $10.8M | $3.73M | $3.87M |
| Depreciation and amortization | $27.2M | $19.8M | $8.18M | $3.48M | $1.82M |
| Ebitda | $148.5M | $70M | -$-7.7M | -$-28.96M | -$-38.49M |
| Operating income | $108.6M | $37.5M | -$-28.73M | -$-31.44M | -$-39.43M |
| Total other income/expenses, net | -$-1.06M | -$-1.72M | $2.06M | -$-4.73M | -$-4.75M |
| Income before tax | $107.5M | $35.8M | -$-26.67M | -$-36.16M | -$-44.18M |
| Income tax expense | -$-82.77M | $320K | -$-1.64M | $70K | $40K |
| Net income | $190.3M | $35.5M | -$-25.03M | -$-36.23M | -$-44.22M |
| Weighted average shares outstanding | $34M | $33.2M | $32.5M | $29.6M | $27.6M |
| Weighted average diluted shares outstanding | $40.5M | $35.2M | $32.5M | $29.6M | $27.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $488.4M | $336.7M | $394.8M | $201.2M | $92.5M |
| Net receivables | $84.3M | $97.7M | $63.6M | $27.6M | $5.93M |
| Inventory | $48.9M | $46.6M | $44.2M | $20.6M | $14.9M |
| Total current assets | $637.8M | $497.2M | $510.7M | $252.3M | $118.7M |
| Property, plant and equipment, net | $332.8M | $292.5M | $180.5M | $24.4M | $15.7M |
| Goodwill and intangible assets | $13.5M | $13.7M | $14.3M | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $500K | $500K |
| Total non-current assets | $430.6M | $306.9M | $195.4M | $24.9M | $16.2M |
| Total assets | $1.07B | $804.1M | $706.1M | $277.2M | $134.9M |
| Accounts payable | $10.4M | $10.3M | $12.7M | $3.34M | $6.65M |
| Short-term debt | $13.3M | $2.73M | $2.04M | $1.44M | $0.00 |
| Deferred revenue | $2.9M | $1.74M | $1.96M | $240K | $250K |
| Total current liabilities | $89.3M | $59.9M | $54.9M | $23.7M | $23.2M |
| Long-term debt | $456.4M | $515.6M | $513.9M | $66.1M | $43.8M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $506M | $515.6M | $513.9M | $66.1M | $43.8M |
| Capital lease obligations | $0.00 | $6.25M | $9.74M | $8.86M | $8.6M |
| Total liabilities | $595.3M | $575.5M | $568.9M | $89.8M | $67M |
| Common stock | $750.9M | $697.2M | $641.1M | $666.3M | $510.5M |
| Retained earnings | -$-277.95M | -$-468.24M | -$-503.7M | -$-478.68M | -$-442.45M |
| Accumulated other comprehensive income (loss) | $120K | -$-360K | -$-200K | -$-230K | -$-190K |
| Total equity | $473.1M | $228.6M | $137.2M | $187.4M | $67.9M |
| Total investments | $0.00 | $0.00 | $0.00 | $500K | $67.4M |
| Total debt | $469.7M | $518.3M | $516M | $67.6M | $43.8M |
| Net debt | -$-18.68M | $181.6M | $121.1M | -$-133.63M | $18.2M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $190.3M | $35.5M | -$-25.03M | -$-36.23M | -$-44.22M |
| Depreciation and amortization | $27.2M | $19.8M | $8.18M | $3.48M | $1.82M |
| Stock-based compensation | $36.9M | $33.2M | $19.8M | $10.3M | $6.88M |
| Change in working capital | $17.3M | -$-45M | -$-44.35M | -$-26.76M | $3M |
| Accounts receivable | $14M | -$-34.31M | -$-33.82M | -$-21.68M | $840K |
| Inventory | -$-7.72M | -$-8.35M | -$-28.09M | -$-8.02M | -$-4.89M |
| Accounts payable | -$-20K | -$-1.4M | $6.96M | -$-3.27M | $5.09M |
| Net cash provided by operating activities | $192.8M | $48.8M | -$-13.03M | -$-45.82M | -$-28.86M |
| Investments in property, plant and equipment | -$-59.25M | $0.00 | -$-151.85M | -$-11.91M | -$-3.52M |
| Acquisitions, net | $0.00 | $440K | -$-14.89M | $110K | $0.00 |
| Net cash used for investing activities | -$-59.25M | -$-129.3M | -$-193.95M | $54.5M | $29.3M |
| Common stock issued | $0.00 | $22.9M | $7.11M | $139.9M | $1.39M |
| Common stock repurchased | -$-140K | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $16.9M | $22.9M | $400.4M | $167.9M | $1.39M |
| Net change in cash | $151.7M | -$-58.16M | $193.6M | $175.6M | $1M |
| Cash at end of period | $488.9M | $337.2M | $395.3M | $201.7M | $26.1M |
| Operating cash flow | $192.8M | $48.8M | -$-13.03M | -$-45.82M | -$-28.86M |
| Capital expenditure | -$-59.25M | -$-129.74M | -$-179.06M | -$-11.91M | -$-3.52M |
| Free cash flow | $133.6M | -$-80.94M | -$-192.09M | -$-57.72M | -$-32.38M |
Line items
Line items
Line items
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- CEO
- Waleed H. Hassanein
- Employees
- 898
- Beta
- 1.88
Explore
Frequently asked questions
What is the intrinsic value of TransMedics Group, Inc. (TMDX)?
TransMedics Group, Inc. (TMDX) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is TMDX undervalued?
TMDX trades at a price of $85.25 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.